Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.
|Number of pages||4|
|Journal||Diagnostic Microbiology and Infectious Disease|
|State||Published - Apr 2019|
Bibliographical noteFunding Information:
We would like to acknowledge Julie A. Ribes, MD, PhD, and the UK HealthCare microbiology laboratory for their assistance in collection and testing of isolates. We also thank Sang Usayaporn, PharmD, and our pharmacy students/residents Matthew Brignola, Chanah K. Gallagher, J. Emery McVicar, Zachary J. Haffler, Chase N. Ayres, Eric R. Gregory, Aidan Sturgill, and Thien-Nam T. To for excellent technical assistance. This material is, in part, the result of work supported with resources and use of facilities at the Lexington, KY, VA Medical Center. The data and results of this study were presented at ASM Microbe 2018. Poster: AAR04-528. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declarations of interest: none.
© 2018 Elsevier Inc.
- Carbapenem-resistant Enterobacteriaceae
- Polymyxin B
- Time kill
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases